EATG » FDA accepts sNDAs for PIFELTRO™ and DELSTRIGO™

FDA accepts sNDAs for PIFELTRO™ and DELSTRIGO™

U.S. FDA accepts sNDAs for PIFELTRO™ (doravirine) and DELSTRIGO™ (doravirine/lamivudine/tenofovir disoproxil fumarate)

–Potential new indication would expand use to allow treatment-experienced adults living with HIV-1 whose virus is suppressed to switch to PIFELTRO (in combination with other antiretrovirals) or DELSTRIGO

Read the full press release here.


 

Source:
Merck
News categories: HIV treatment, EMA/FDA